CARDIOVASCULAR JOURNAL OF AFRICA • Volume 34, No 2, May/June 2023 128 AFRICA practitioner. BMC Fam Pract 2020; 21(1): 198. 33. Gertz MA. Cardiac amyloidosis. Heart Fail Clin 2022; 18(3): 479–488. 34. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Eng J Med 2018; 379(11): 1007–1016. 35. Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139(4): 431–443. 36. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018; 379(1): 22–31. 37. Budhram S, Krishundutt P. A three-year audit of pregnancy outcomes in women with pulmonary hypertension admitted to the high-risk obstetric unit at Inkosi Albert Luthuli Central Hospital, KwaZulu-Natal, South Africa. Cardiovasc J Afr 2022; 33: 1–8. 38. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43(38): 3618–3731. 39. Strange G, Playford D, Stewart S, Deague JA, Nelson H, Kent A, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart 2012; 98(24): 1805–1811. 40. Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 2011; 139(5): 988–993. 41. Truby LK, Rogers JG. Advanced heart failure: epidemiology, diagnosis, and therapeutic approaches. J Am Coll Cardiol Heart Fail 2020; 8(7): 523–536. 42. Baumwol J. ‘I Need Help’ – A mnemonic to aid timely referral in advanced heart failure. J Heart Lung Transplant 2017; 36(5): 593–594. 43. Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv 2019; 94(1): 29–37. 44. Givertz MM, DeFilippis EM, Colvin M, Darling CE, Elliott T, Hamad E, et al. HFSA/SAEM/ISHLT clinical expert consensus document on the emergency management of patients with ventricular assist devices. J Heart Lung Transplant 2019; 38(7): 677–698. 45. Peberdy MA, Gluck JA, Ornato JP, Bermudez CA, Griffin RE, Kasirajan V, et al. Cardiopulmonary resuscitation in adults and children with mechanical circulatory support: a scientific statement from the American Heart Association. Circulation 2017; 135(24): e1115–e1134. 46. Pettit SJ, Petrie MC, Connelly DT, Japp AG, Payne JR, Haj-Yahia S, et al. Use of implantable cardioverter defibrillators in patients with left ventricular assist devices. Eur J Heart Fail 2012; 14(7): 696–702. 47. Molina EJ, Shah P, Kiernan MS, Cornwell WK, 3rd, Copeland H, Takeda K, et al. The Society of Thoracic Surgeons Intermacs 2020 annual report. Ann Thorac Surg 2021; 111(3): 778–792. 48. Mehra MR, Uriel N, Naka Y, Cleveland JC, Jr, Yuzefpolskaya M, Salerno CT, et al. A fully magnetically levitated left ventricular assist device – final report. N Engl J Med 2019; 380(17): 1618–1627. 49. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005. Circ Heart Fail 2009; 2(1): 3–10. 50. Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012; 5(2): 241–248. 51. Slaughter MS, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2013; 32(7): 675–683. 52. Acharya D, Loyaga-Rendon R, Morgan CJ, Sands KA, Pamboukian SV, Rajapreyar I, et al. INTERMACS analysis of stroke during support with continuous-flow left ventricular assist devices: risk factors and outcomes. J Am Coll Cardiol Heart Fail 2017; 5(10): 703–711. 53. Teuteberg JJ, Slaughter MS, Rogers JG, McGee EC, Pagani FD, Gordon R, et al. The HVAD left ventricular assist device: risk factors for neurological events and risk mitigation strategies. J Am Coll Cardiol Heart Fail 2015; 3(10): 818–828. 54. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361(23): 2241–2251. 55. Coffin ST, Haglund NA, Davis ME, Xu M, Dunlay SM, Cowger JA, et al. Adverse neurologic events in patients bridged with long-term mechanical circulatory support: A device-specific comparative analysis. J Heart Lung Transplant 2015; 34(12): 1578–1585. 56. Rame JE, Pagani FD, Kiernan MS, Oliveira GH, Birati EY, Atluri P, et al. Evolution of late right heart failure with left ventricular assist devices and association with outcomes. J Am Coll Cardiol 2021; 78(23): 2294–2308. 57. Rich JD, Gosev I, Patel CB, Joseph S, Katz JN, Eckman PM, et al. The incidence, risk factors, and outcomes associated with late right-sided heart failure in patients supported with an axial-flow left ventricular assist device. J Heart Lung Transplant 2017; 36(1): 50–58. 58. Khush KK, Hsich E, Potena L, Cherikh WS, Chambers DC, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult heart transplantation report – 2021; Focus on recipient characteristics. J Heart Lung Transplant 2021; 40(10): 1035–1049. 59. Watson CJ, Dark JH. Organ transplantation: historical perspective and current practice. Br J Anaesth 2012; 108(Suppl 1): i29–42. 60. Agbor-Enoh S, Shah P, Tunc I, Hsu S, Russell S, Feller E, et al. Cell-free DNA to detect heart allograft acute rejection. Circulation 2021; 143(12): 1184–1197. 61. Moon S, Mariat S, Kamae I, Pedersen HB. Defining the concept of fair pricing for medicines. Br Med J 2020; 368: l4726. 62. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, FernandezOrtiz A, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022; 387(11): 967–977. 63. Pandey A, Keshvani N, Wang TJ. Should polypills be used for heart failure with reduced ejection fraction? Circulation 2022; 146(4): 276–278.
RkJQdWJsaXNoZXIy NDIzNzc=